Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder

Insomnia Disorder Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled Phase Ⅰb/Ⅱ Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10506 in Chinese Adult Participants With Insomnia Disorder

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06279286
• Other study ID #: HS-10506-201
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: May 2024
• Est. completion date: January 2025

Study information

• Verified date: February 2024
• Source: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this phase Ⅰb/Ⅱ study is to investigate the safety, tolerability, pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) after multiple dose administration and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) measured by polysomnography (PSG) in Chinese adult participants with insomnia disorder.

Description:

This study consists of two stages: phase Ib and phase II. Primary objective of phase Ib Study is to assess the safety, tolerability of HS-10506 in subjects with insomnia disorder. .

Primary objective of phase II Study is to assess the efficacy of HS-10506 in subjects with insomnia disorder.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 312
• Est. completion date: January 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

1. Subjects must be 18 to 64 years of age, inclusive

2. Subjects are required to voluntarily sign the informed consent form;

3. Body mass index (BMI): for phase Ib, males must weigh at least 50 kilogram (kg), females at least 45 kg, and BMI (weight/height2 [kg/m2]) must be in the range of 18 to 30 kg/m2 (inclusive) for both gender; for phase II, BMI must be in the range of 18 to 35 kg/m2 (inclusive);

4. Participant must meet Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5) criteria for insomnia disorder;

5. Participants must have Insomnia Severity Index (ISI) scores >=15 at screening and baseline;

6. Subjective sleep assessment: for phase Ib, subjects must have a self-reported sleep latency (sSOL) >= 30 minutes, a subjective sleep awakening time (sWASO) >= 30 minutes, and a subjective total sleep time (sTST) =< 6.5 hours using the sleep diary for at least three nights every week in the last 1 month prior to screening; For phase II, subjects must have an sSOL >= 30 minutes, sWASO >= 30 minutes, and sTST =< 6.5 hours for at least three nights every week within one month prior to screening; and sSOL >= 30 minutes, sWASO >= 30 minutes, and sTST =< 6.5 hours for at least 3 nights from sleep diary in the last 7 days;

7. PSG: for phase Ib, participants must demonstrate an LPS >= 20 minutes, TST < 420 minutes, and WASO >= 30 minutes at screening; for phase II, participants must demonstrate a 2-night mean LPS >= 30 minutes with neither night < 20 minutes, a 2-night mean TST =< 6.5 hours with neither night > 7 hours and a 2-night mean WASO >= 30 minutes with neither nigh < 20 minutes.

Exclusion Criteria:

1. Has history of or current sleep-wake disorders or sleep-related breathing disorders other than insomnia disorder, such as restless legs syndrome, periodic limb movement disorder, circadian rhythm disorder, narcolepsy, rapid eye movement sleep phase (REM) behavioral disorders, and obstructive sleep apnea;

2. Has a hypopnea index (AHI) >10 times/hour or periodic leg movement index (PLMI) >10 times/hour monitored by PSG at screening or run-in period;

3. Has history of or current neurodevelopmental retardation, cognitive impairment, epilepsy, schizophrenia, bipolar disorder, hyperthyroidism, cancer, severe cardio-cerebrovascular diseases or respiratory diseases; or clinically significant and/or unstable neurological, psychiatric, respiratory, cardiovascular, digestive, immunologic, urologic, endocrine diseases within the past 3 months prior to screening; or other systemic diseases that are inappropriate for the study;

4. (For phase II only) Has a Hamilton Anxiety Scale (HAMA) score >= 14 or Hamilton Depression Scale (HAMD-17) score >= 18;

5. Use of any medication that may affect the pharmacokinetics of HS-10506 within the past 2 weeks or 5 half-lives of the medication;

6. Use of any medication that may affect sleep-wake function, or any other prohibited central nervous system active medications within 1 week or 5 half-lives of the medication;

7. Has received systemic hypnotherapy, cognitive behavioral therapy (CBT), or other non-pharmacological treatments for insomnia in last 4 weeks or have plans during the study;

8. Working across 3 or more time zones or shift work within 2 weeks prior to screening;

9. Regularly naps more than 3 naps per week for > 1 hour each time within the past 2 weeks prior to screening;

10. Has a risk of suicide according to the Columbia Suicide Severity Rating Scale (C-SSRS), or has a high risk of suicide at the discretion of the investigator;

11. Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.

Related Conditions & MeSH terms

• Insomnia Disorder
• Sleep Initiation and Maintenance Disorders

Intervention

Drug:
• HS-10506
HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.
• Placebo
Placebo, placebo tablets matching the HS-10506 tablets

Locations

Country	Name	City	State
China	Xuanwu Hospital Capital Medical University	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and severity of adverse events (AE)	An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.	Baseline up to the end of the study (3 days after the last dose) or early withdrawal
Primary	Incidence and severity of serious adverse events (SAE)	An SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.	Baseline up to the end of the study (3 days after the last dose) or early withdrawal
Primary	Changes in laboratory test before and after drug administration	Number of participants with clinically significant laboratory abnormalities, including complete blood cell count, urinalysis, serum chemistry, coagulation function were reported.	Baseline up to the end of the study (3 days after last dose) or early withdrawal
Primary	Changes in ECG before and after drug administration	Number of participants with clinically significant ECG abnormalities were reported.	Baseline up to the end of the study (3 days after last dose) or early withdrawal
Primary	Changes in Karolinska Sleepiness Scale (KSS) scores before and after drug administration	The KSS is a patient-reported assessment of drowsiness level at the time of scale administration.	From start of the drug administration to the next day of the last dose or early withdrawal
Primary	Change from baseline in the mean LPS measured by PSG on Night 13 and Night 14	LPS is the time in minutes from 'lights out' that marks the starting of total recording time to the first epoch recorded as sleep.	Baseline, Night 13& Night 14
Secondary	The maximum plasma concentration (C[max])	The C[max] is the maximum observed plasma concentration and will be determined for HS-10506.	Baseline up to 48 hours after the last dose or early withdrawal
Secondary	Time to reach the maximum plasma concentration (T[max])	Time to reach maximum observed plasma concentration (T[max]) of HS-10506.	Baseline up to 48 hours after the last dose or early withdrawal
Secondary	Area under the plasma concentration-time curve from time zero to last time of quantifiable concentration (AUC[0-t])	Area under the concentration-time curve from time zero to last time of quantifiable concentration of HS-10506.	Baseline up to 48 hours after the last dose or early withdrawal
Secondary	Terminal elimination half-life (t1/2)	Apparent terminal elimination half-life of HS-10506.	Baseline up to 48 hours after the last dose or early withdrawal
Secondary	Change in latency to persistent sleep (LPS) relative to baseline on night 5 of PSG monitoring	Latency to persistent sleep (LPS) is the time in minutes from 'lights out' that marks the starting of total recording time to the first epoch recorded as sleep over PSG assessment.	Baseline and Night 5
Secondary	Change in Wake After Sleep Onset (WASO) relative to baseline on night 5 of PSG monitoring	Wake After Sleep Onset (WASO) is defined as the duration of wakefulness from the onset of persistent sleep over the PSG assessment.	Baseline and Night 5
Secondary	Change from baseline in mean LPS measured by PSG	Latency to Persistent Sleep (LPS) is the time in minutes from 'lights out' that marks the starting of total recording time to the first epoch recorded as sleep over PSG assessment.	Baseline up to 28 days.
Secondary	Change from baseline in mean TST measured by PSG	Total sleep time (TST) is the total amount of sleep time scored during the total recording time over PSG assessment.	Baseline up to 28 days.
Secondary	Change from baseline in mean WASO measured by PSG	Wake after initial sleep onset (WASO) is defined as the duration of wakefulness from the onset of persistent sleep over PSG assessment.	Baseline up to 28 days.
Secondary	Change from baseline in the mean values of self-reported sleep-onset latency (sSOL) recorded in the sleep diary	Change from baseline in the mean values of self-reported sleep-onset latency (sSOL) measured by sleep diary.	Baseline up to 28 days.
Secondary	Change from baseline in the mean values of self-reported total sleep time (sTST) recorded in the sleep diary	Change from baseline in mean self-reported total sleep time measured by sleep diary.	Baseline up to 28 days.
Secondary	Incidence and severity of adverse events (AE)	An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.	Baseline up to 28 days.
Secondary	Incidence and severity of serious adverse events (SAE)	An SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.	Baseline up to 28 days.